Key result
ATTR-CM links to ~26% more annual hospital days and higher inpatient costs versus non-amyloid HF.
Why the study?
ATTR-CM is a progressive, fatal disease with a substantial healthcare burden, but its healthcare resource utilization and costs compared with non-amyloid HF and individuals without HF remained to be determined.
Does ATTR-CM increase health care resource utilization and costs compared to non-amyloid heart failure and the general population?
Cohort (n=13,713)
Does ATTR-CM increase health care resource utilization and costs compared to non-amyloid heart failure and the general population?
Absolute Event Rate: 10.6% vs 8.4%
p-value: p=<0.001
ATTR-CM is associated with significantly higher healthcare resource utilization and costs compared to non-amyloid heart failure and the general population.
ATTR-CM hospitalizations exceed non-amyloid HF length of stay; hypothesis-generating for resource impact of targeted therapies.
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive, fatal disease associated with a substantial health care system burden. The aim of this study was to compare health care resource utilization and associated costs among individuals with ATTR‐CM, with non‐amyloid heart failure (HF), and without HF in the United States. Methods Optum's de‐identified Clinformatics Data Mart Database (January 2016 to September 2023) was used to identify patients with ATTR‐CM based on HF and/or cardiomyopathy claims within 2 years of the first ATTR diagnosis. Patients with ATTR‐CM were matched to patients with non‐amyloid HF (HF/cardiomyopathy without ATTR) and non‐HF controls using 1:1 propensity score matching. All‐cause and cardiovascular‐related hospitalizations and costs were compared during follow‐up. Results Each matched cohort included 4571 patients (mean age, 75.3–75.5 years; 56.0%–56.6% male; mean follow‐up: 2.9–3.2 years). The ATTR‐CM, non‐amyloid HF, and non‐HF cohorts had 3.3, 2.7, and 1.5 all‐cause hospitalizations per patient during follow‐up, respectively. Compared with non‐amyloid HF, patients with ATTR‐CM had a longer mean length of stay per hospitalization (all‐cause and cardiovascular‐related: 8.0 versus 7.5 days; P <0.001), more mean days hospitalized annually per patient (all‐cause: 10.6 versus 8.4; cardiovascular‐related: 10.5 versus 8.3 [both P <0.001]), and higher mean annual inpatient hospitalization costs per patient (all‐cause: $42 868 versus $36 061; cardiovascular‐related: $42 841 versus $36 027 [both P <0.001]). In ATTR‐CM subgroups, mean cardiovascular‐related length of stay and days hospitalized were higher among patients aged 46 to 64 years and 65 to 80 years (versus >80 years), Black patients (versus White patients), and patients in the Northeast or South US regions (versus West regions). Conclusions ATTR‐CM is associated with a higher health care resource utilization/cost burden than non‐amyloid HF and the general population.
No takes yet. Share an insight, caveat, or question.
Grodin et al. (2026) conducted a cohort in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=13,713). Transthyretin amyloid cardiomyopathy (ATTR-CM) vs. Non-amyloid heart failure (HF) and non-HF controls was evaluated on Mean days hospitalized annually per patient (all-cause) (p=<0.001). ATTR-CM was associated with more mean days hospitalized annually per patient compared with non-amyloid HF (10.6 vs 8.4 days; P<0.001) and higher annual inpatient costs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: